Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst M. Colonnese forecasts that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($1.39) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.94) EPS.
Separately, Chardan Capital raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy”.
Bradmer Pharmaceuticals Price Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
